Literature DB >> 14612424

mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF.

Katherine M Hannan1, Yves Brandenburger, Anna Jenkins, Kerith Sharkey, Alice Cavanaugh, Lawrence Rothblum, Tom Moss, Gretchen Poortinga, Grant A McArthur, Richard B Pearson, Ross D Hannan.   

Abstract

Mammalian target of rapamycin (mTOR) is a key regulator of cell growth acting via two independent targets, ribosomal protein S6 kinase 1 (S6K1) and 4EBP1. While each is known to regulate translational efficiency, the mechanism by which they control cell growth remains unclear. In addition to increased initiation of translation, the accelerated synthesis and accumulation of ribosomes are fundamental for efficient cell growth and proliferation. Using the mTOR inhibitor rapamycin, we show that mTOR is required for the rapid and sustained serum-induced activation of 45S ribosomal gene transcription (rDNA transcription), a major rate-limiting step in ribosome biogenesis and cellular growth. Expression of a constitutively active, rapamycin-insensitive mutant of S6K1 stimulated rDNA transcription in the absence of serum and rescued rapamycin repression of rDNA transcription. Moreover, overexpression of a dominant-negative S6K1 mutant repressed transcription in exponentially growing NIH 3T3 cells. Rapamycin treatment led to a rapid dephosphorylation of the carboxy-terminal activation domain of the rDNA transcription factor, UBF, which significantly reduced its ability to associate with the basal rDNA transcription factor SL-1. Rapamycin-mediated repression of rDNA transcription was rescued by purified recombinant phosphorylated UBF and endogenous UBF from exponentially growing NIH 3T3 cells but not by hypophosphorylated UBF from cells treated with rapamycin or dephosphorylated recombinant UBF. Thus, mTOR plays a critical role in the regulation of ribosome biogenesis via a mechanism that requires S6K1 activation and phosphorylation of UBF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612424      PMCID: PMC262650          DOI: 10.1128/MCB.23.23.8862-8877.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  66 in total

1.  TIF-IA, the factor mediating growth-dependent control of ribosomal RNA synthesis, is the mammalian homolog of yeast Rrn3p.

Authors:  J Bodem; G Dobreva; U Hoffmann-Rohrer; S Iben; H Zentgraf; H Delius; M Vingron; I Grummt
Journal:  EMBO Rep       Date:  2000-08       Impact factor: 8.807

Review 2.  Promotion and regulation of ribosomal transcription in eukaryotes by RNA polymerase I.

Authors:  T Moss; V Y Stefanovsky
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1995

3.  The RNA polymerase I transcription factor UBF is the product of a primary response gene.

Authors:  M Glibetic; L Taylor; D Larson; R Hannan; B Sells; L Rothblum
Journal:  J Biol Chem       Date:  1995-03-03       Impact factor: 5.157

Review 4.  Regulation of translation initiation by FRAP/mTOR.

Authors:  A C Gingras; B Raught; N Sonenberg
Journal:  Genes Dev       Date:  2001-04-01       Impact factor: 11.361

5.  Rapamycin, wortmannin, and the methylxanthine SQ20006 inactivate p70s6k by inducing dephosphorylation of the same subset of sites.

Authors:  J W Han; R B Pearson; P B Dennis; G Thomas
Journal:  J Biol Chem       Date:  1995-09-08       Impact factor: 5.157

6.  Angiotensin II-induced hypertrophy of rat vascular smooth muscle is associated with increased 18 S rRNA synthesis and phosphorylation of the rRNA transcription factor, upstream binding factor.

Authors:  J C Hershey; M Hautmann; M M Thompson; L I Rothblum; T A Haystead; G K Owens
Journal:  J Biol Chem       Date:  1995-10-20       Impact factor: 5.157

7.  Regulation of rDNA transcription factors during cardiomyocyte hypertrophy induced by adrenergic agents.

Authors:  R D Hannan; J Luyken; L I Rothblum
Journal:  J Biol Chem       Date:  1995-04-07       Impact factor: 5.157

8.  Protein kinase CK2: biphasic kinetics with peptide substrates.

Authors:  T Tiganis; C M House; B E Kemp
Journal:  Arch Biochem Biophys       Date:  1996-01-15       Impact factor: 4.013

9.  Activation of mammalian ribosomal gene transcription requires phosphorylation of the nucleolar transcription factor UBF.

Authors:  R Voit; A Kuhn; E E Sander; I Grummt
Journal:  Nucleic Acids Res       Date:  1995-07-25       Impact factor: 16.971

10.  The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain.

Authors:  R B Pearson; P B Dennis; J W Han; N A Williamson; S C Kozma; R E Wettenhall; G Thomas
Journal:  EMBO J       Date:  1995-11-01       Impact factor: 11.598

View more
  188 in total

1.  Possible dual regulatory circuits involving AtS6K1 in the regulation of plant cell cycle and growth.

Authors:  Yun-jeong Shin; Sunghan Kim; Hui Du; Soonyoung Choi; Desh Pal S Verma; Choong-Ill Cheon
Journal:  Mol Cells       Date:  2012-04-17       Impact factor: 5.034

2.  Nuclear-localized calcineurin homologous protein CHP1 interacts with upstream binding factor and inhibits ribosomal RNA synthesis.

Authors:  Maite Jiménez-Vidal; Jyoti Srivastava; Luanna K Putney; Diane L Barber
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

Review 3.  Emerging roles of the neuronal nucleolus.

Authors:  Michal Hetman; Maciej Pietrzak
Journal:  Trends Neurosci       Date:  2012-02-02       Impact factor: 13.837

4.  Myb-binding protein 1a (Mybbp1a) regulates levels and processing of pre-ribosomal RNA.

Authors:  Julia Hochstatter; Michael Hölzel; Michaela Rohrmoser; Lothar Schermelleh; Heinrich Leonhardt; Rebecca Keough; Thomas J Gonda; Axel Imhof; Dirk Eick; Gernot Längst; Attila Németh
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

5.  Protein kinase Cι promotes UBF1-ECT2 binding on ribosomal DNA to drive rRNA synthesis and transformed growth of non-small-cell lung cancer cells.

Authors:  Verline Justilien; Kayla C Lewis; Kayleah M Meneses; Lee Jamieson; Nicole R Murray; Alan P Fields
Journal:  J Biol Chem       Date:  2020-04-29       Impact factor: 5.157

Review 6.  Signaling by target of rapamycin proteins in cell growth control.

Authors:  Ken Inoki; Hongjiao Ouyang; Yong Li; Kun-Liang Guan
Journal:  Microbiol Mol Biol Rev       Date:  2005-03       Impact factor: 11.056

7.  Acrofacial Dysostosis, Cincinnati Type, a Mandibulofacial Dysostosis Syndrome with Limb Anomalies, Is Caused by POLR1A Dysfunction.

Authors:  K Nicole Weaver; Kristin E Noack Watt; Robert B Hufnagel; Joaquin Navajas Acedo; Luke L Linscott; Kristen L Sund; Patricia L Bender; Rainer König; Charles M Lourenco; Ute Hehr; Robert J Hopkin; Dietmar R Lohmann; Paul A Trainor; Dagmar Wieczorek; Howard M Saal
Journal:  Am J Hum Genet       Date:  2015-04-23       Impact factor: 11.025

8.  Activation of protein synthesis in cardiomyocytes by the hypertrophic agent phenylephrine requires the activation of ERK and involves phosphorylation of tuberous sclerosis complex 2 (TSC2).

Authors:  Mark Rolfe; Laura E McLeod; Phillip F Pratt; Christopher G Proud
Journal:  Biochem J       Date:  2005-06-15       Impact factor: 3.857

9.  Mammalian target of rapamycin (mTOR) induces proliferation and de-differentiation responses to three coordinate pathophysiologic stimuli (mechanical strain, hypoxia, and extracellular matrix remodeling) in rat bladder smooth muscle.

Authors:  Karen J Aitken; Cornelia Tolg; Trupti Panchal; Bruno Leslie; Jeffery Yu; Mohamed Elkelini; Nesrin Sabha; Derrick J Tse; Armando J Lorenzo; Magdy Hassouna; Darius J Bägli
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

10.  Stimulation of skeletal muscle myofibrillar protein synthesis, p70 S6 kinase phosphorylation, and ribosomal protein S6 phosphorylation by inhibition of myostatin in mature mice.

Authors:  Stephen Welle; Kerri Burgess; Sangeeta Mehta
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-01-13       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.